Regeneron Pharmaceuticals (REGN) plunged 10% Friday afternoon after trading was briefly halted for volatility, after word got out that the FDA is investigating its cholesterol-drug candidate for adverse effects. The item was buried deep in a 20-F form Regeneron’s big-pharma partner Sanofi (SNY) filed Friday. Under a discussion of the two firms’ collaboration on alirocumab, a monoclonal antibody of a type called PCSK9 for treating high cholesterol,
Big pharma Eli Lilly (LLY) said Wednesday that its drug candidate ramucirumab improved the survival of lung-cancer patients in a late-stage study. Lilly stock gapped up 3% in early trading on the stock market today. The study looked at patients with metastatics non-small-cell lung cancer (NSCLC) who had failed a previous round of platinum-based chemotherapy. One group of patients took standard cancer drug docetaxel (best known as Sanofi’s (SNY)
Cubist Pharmaceuticals (CBST) reported positive late-stage trial results for its antibiotic candidate Monday, sending Cubist stock to a 13-year high on the stock market today. The drug, ceftolozane/tazobactam, known in the industry as tol/taz for short, was tested in patients with urinary tract infections and compared to levofloxacin, which is known commercially as Johnson & Johnson’s (JNJ) Levaquin and Sanofi’s (SNY) Tavanic. Cubist said tol/taz